Featured Research

from universities, journals, and other organizations

Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD, review suggests

Date:
May 10, 2011
Source:
Wiley-Blackwell
Summary:
Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but does not increase general quality of life, according to a systematic review.

Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but does not increase general quality of life. These are the findings of a new systematic review by Cochrane researchers.

COPD is one of the leading causes of global morbidity and mortality, resulting in a growing social and economic burden (GOLD 2005). In 2002, research published by the WHO estimated that it was the fifth leading cause of death worldwide, responsible for approximately 4.8% of total deaths worldwide, and predicted that it would become the fourth leading cause of death by 2030.

COPD reduces lung function, quality of life and life expectancy. Apart from stopping smoking, there are no other treatments that slow the decline of lung function.

Roflumilast and cilomilast are members of a new class of medicines, and trials have now evaluated their safety and performance. Led by Dr Phillippa Poole of the University of Auckland, New Zealand, a team of researchers looked at data from nine trials of roflumilast and 14 trials of cilomilast involving over 15,000 patients.

Treatment with a PDE4 inhibitor was associated with a reduced likelihood of COPD exacerbation, but more participants in the treatment groups experienced non-serious adverse events compared with controls, particularly gastrointestinal symptoms and headache. Roflumilast was associated with weight loss during the trial period.

"Phosphodiesterase 4 inhibitors join an increasing list of treatments for COPD that improve lung function slightly and reduce exacerbations, but have not yet been shown to increase life expectancy," says Dr Poole.

She points out that so far trials have only run for one year or less, and that there is a need to look at longer-lasting effects. However there could be a problem in gathering that data. "Encouraging people with COPD to continue to take these medicines in the absence of symptomatic relief may be challenging," says Dr Poole.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD, review suggests." ScienceDaily. ScienceDaily, 10 May 2011. <www.sciencedaily.com/releases/2011/05/110510211553.htm>.
Wiley-Blackwell. (2011, May 10). Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD, review suggests. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2011/05/110510211553.htm
Wiley-Blackwell. "Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD, review suggests." ScienceDaily. www.sciencedaily.com/releases/2011/05/110510211553.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins